Clinical trial
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin…
NCT00242580 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00242580 |
|---|---|
| Title | A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib |
| Official title | A 24-month Randomized, Double-masked, Sham Controlled, Multicenter, Phase IIIB Study Comparing Photodynamic Therapy With Verteporfin (Visudyne®) Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1 mg and 4 mg) Versus Visudyne® Plus Intravitreal Pegaptanib(Macugen®) in… |
| Acronym | VERITAS |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Collaborators | QLT Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration, Choroidal Neovascularization |
| Intervention type | Drug |
| Interventions | Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide |
| Enrollment | 111 |
| Start date | Sep 1, 2005 |
| Primary completion | Jan 1, 2008 |
| First posted | Oct 20, 2005 |
| Last update posted | Mar 31, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: